1429334-00-8

Basic information

• Product Name: AcetaMide, N-[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-
• Synonyms: AcetaMide, N-[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-;(S)-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)acetamide;N-[[(5S)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-acetamide;Rivaroxaban AcetaMide Impurity;(S)-N-[{3-(4-(3-oxomorpholin-4-yl)phenyl)-2-oxo-1,3-oxazolidin-5-yl}methyl]acetamide
• CAS NO: 1429334-00-8
• Molecular Formula: C₁₆H₁₉N₃O₅
• Molecular Weight: 333.33916
• Mol File: 1429334-00-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 686.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.326±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 15.53±0.46(Predicted)
• CAS DataBase Reference: AcetaMide, N-[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: AcetaMide, N-[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-(1429334-00-8)
• EPA Substance Registry System: AcetaMide, N-[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-(1429334-00-8)

Safety Data

• Hazardous Substances Data: 1429334-00-8(Hazardous Substances Data)

Usage

Description

AcetaMide, N-[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]is a chemical compound that serves as an impurity in Rivaroxaban (R538000), a novel antithrombotic agent. Rivaroxaban is a highly potent and selective, direct FXa inhibitor, which plays a crucial role in the prevention and treatment of various thrombotic disorders.

Uses

Used in Pharmaceutical Industry:
AcetaMide, N-[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]is used as an impurity in the development and production of Rivaroxaban, a novel antithrombotic agent. The presence of this compound in Rivaroxaban is essential for its function as a highly potent and selective, direct FXa inhibitor, which aids in the prevention and treatment of thrombotic disorders.
In the pharmaceutical industry, the compound is utilized to enhance the efficacy of Rivaroxaban as an antithrombotic agent. Its role in the development of this medication is significant, as it contributes to the overall effectiveness of the drug in treating and preventing thrombotic conditions.
Furthermore, the compound may also be used in research and development for the creation of new antithrombotic agents or for the improvement of existing ones. Its presence in Rivaroxaban provides valuable insights into the chemical properties and interactions that can be leveraged to develop more effective medications for thrombotic disorders.

Upstream product

• 446292-10-0 4-[4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholine-3-one 
• 75-36-5 acetyl chloride 
• 898543-06-1 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidine-3-yl]phenyl}morpholin-3-one hydrochloride 
• 224323-47-1 (S)-N-(3-chloro-2-hydroxy-1-propyl)acetamide 
• 1429334-02-0 N-[(2R)-2-hydroxy-3-{[4-(3-oxomorpholin-4-yl)phenyl]amino}propyl]acetamide 
• 530-62-1 1,1'-carbonyldiimidazole 
• 183805-10-9 N-[(2S)oxiranylmethyl]acetamide 
• 438056-69-0 4-(4-aminophenyl)morpholin-3-one 
• 183905-31-9 N-[(2S)-2-acetoxy-3-chloropropyl]acetamide 
• 1313613-18-1 [4-(3-oxo-morpholin-4-yl)phenyl]carbamic acid benzyl ester 

Downstream Products

• 446292-10-0 4-[4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholine-3-one 

Relevant articles and documents

A related substance [...] F, G synthetic method

The invention provides synthetic methods of related substances F and G of rivaroxaban. With the adoption of the synthetic methods of the related substances F and G of the rivaroxaban, the yield is high, and industrial production and technology transformation are realized easily.

PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF

TThe present invention provides processes for the preparation of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide (I) and intermediates thereof. Also provides novel intermediates and their use in the synthesis of oxazolidine derivatives.